PubRank

APOE ε4 and risk for Alzheimer's disease: do regionally distributed white matter hyperintensities play a role?

PubWeight™: 0.81‹?›

🔗 View Article (PMC 4252241)

Published in Alzheimers Dement on October 07, 2014

Authors

Adam M Brickman1, Nicole Schupf2, Jennifer J Manly3, Yaakov Stern4, José A Luchsinger5, Frank A Provenzano6, Atul Narkhede6, Qolamreza Razlighi7, Lyndsey Collins-Praino7, Sylvaine Artero8, Tasnime N Akbaraly9, Karen Ritchie9, Richard Mayeux10, Florence Portet8

Author Affiliations

1: Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY, USA; G.H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. Electronic address: amb2139@columbia.edu.
2: Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY, USA; G.H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
3: Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY, USA; G.H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
4: Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY, USA; G.H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
5: Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
6: Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
7: Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
8: Inserm, 1061 Neuropsychiatry, La Colombière Hospital, Montpellier, France; Faculty of Medicine University of Montpellier 1, Montpellier, France.
9: Inserm, 1061 Neuropsychiatry, La Colombière Hospital, Montpellier, France; Faculty of Medicine University of Montpellier 1, Montpellier, France; Department of Epidemiology and Public Health, Faculty of Medicine, Imperial College, University College London, London, UK.
10: Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY, USA; G.H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA. Electronic address: rpm2@cumc.columbia.edu.

Articles citing this ↘

The role of APOE in cerebrovascular dysfunction. Acta Neuropathol (2016) 0.84

Peripheral (deep) but not periventricular MRI white matter hyperintensities are increased in clinical vascular dementia compared to Alzheimer's disease. Brain Behav (2016) 0.77

White matter disease in midlife is heritable, related to hypertension, and shares some genetic influence with systolic blood pressure. Neuroimage Clin (2016) 0.75

Introducing Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, an open access journal of the Alzheimer's Association. Alzheimers Dement (Amst) (2015) 0.75

Five-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps? Alzheimers Dement (Amst) (2015) 0.75

A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers. J Alzheimers Dis (2017) 0.75

In Vivo Imaging of Venous Side Cerebral Small-Vessel Disease in Older Adults: An MRI Method at 7T. AJNR Am J Neuroradiol (2017) 0.75

Articles cited by this ↗

Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43

Stereotaxic display of brain lesions. Behav Neurol (2000) 9.20

The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA (1998) 7.81

Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology (2001) 5.98

Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci (2011) 5.64

Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry (2001) 4.51

Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.07

Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology (2005) 4.04

Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron (1993) 3.92

Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology (1995) 3.91

apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest (2008) 3.36

A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci (2011) 3.23

Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology (2006) 3.22

Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl (1996) 3.02

Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke (1984) 2.86

Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan. Arch Neurol (2008) 2.69

Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res (2008) 2.28

Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci (2013) 2.26

Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci (2005) 2.17

Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging (2006) 2.03

Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke (2004) 1.93

Risk factors for vascular dementia and Alzheimer disease. Stroke (2004) 1.92

Sex differences in brain aging: a quantitative magnetic resonance imaging study. Arch Neurol (1998) 1.86

Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci (2012) 1.58

Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. Neuron (1995) 1.56

Prevalence of DSM-IV psychiatric disorder in the French elderly population. Br J Psychiatry (2004) 1.54

Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol (2008) 1.48

Reduction in cerebral blood flow in areas appearing as white matter hyperintensities on magnetic resonance imaging. Psychiatry Res (2009) 1.48

White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol (2013) 1.47

Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol (2012) 1.44

Structural neuroimaging in Altheimer's disease: do white matter hyperintensities matter? Dialogues Clin Neurosci (2009) 1.38

Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants. Biochim Biophys Acta (2011) 1.29

Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology (2013) 1.29

Subclinical cerebrovascular disease in mild cognitive impairment. Neurology (2009) 1.28

Comparison of gray matter and metabolic reduction in mild Alzheimer's disease using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging (2005) 1.27

Quantitative approaches for assessment of white matter hyperintensities in elderly populations. Psychiatry Res (2011) 1.22

APOE genotype and MRI markers of cerebrovascular disease: systematic review and meta-analysis. Neurology (2013) 1.14

Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. Ann Neurol (1994) 1.06

Brain function and cognition in a community sample of elderly Latinos. Neurology (2002) 1.05

Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology (2012) 1.02

A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J Neurol Neurosurg Psychiatry (1998) 1.02

White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment. Alzheimers Dement (2013) 0.92

Superiority of 3-dimensional stereotactic surface projection analysis over visual inspection in discrimination of patients with very early Alzheimer's disease from controls using brain perfusion SPECT. J Nucl Med (2004) 0.91

Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Arch Neurol (1999) 0.90

Effect of the apolipoprotein E epsilon4 allele on white matter hyperintensities in dementia. Stroke (2000) 0.89

Dutch hereditary cerebral amyloid angiopathy: structural lesions and apolipoprotein E genotype. Ann Neurol (1997) 0.84

Spatial distribution of cerebral white matter lesions predicts progression to mild cognitive impairment and dementia. PLoS One (2013) 0.84

White matter lesions in Alzheimer patients are influenced by apolipoprotein E genotype. Dement Geriatr Cogn Disord (1999) 0.84

Genetics of Alzheimer's disease in Caribbean Hispanic and African American populations. Biol Psychiatry (2013) 0.84

Metabolic syndrome and localization of white matter hyperintensities in the elderly population. Alzheimers Dement (2012) 0.82

Are genetic factors important in the aetiology of leukoaraiosis? Results from a memory clinic population. Int J Geriatr Psychiatry (1998) 0.81

Brain tissue volumes by APOE genotype and leisure activity-the AGES-Reykjavik Study. Neurobiol Aging (2011) 0.80

Articles by these authors ⇆

Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence. Neurobiol Aging (2014) 1.08

Cerebral microbleeds in a multiethnic elderly community: demographic and clinical correlates. J Neurol Sci (2014) 0.82